SCHEMBL2384067

SCHEMBL2384067

C[C@H](NC(=O)c1c(O)c2ccc(C(F)(F)F)cc2n(C)c1=O)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.52
EGLN1 Q9GZT9 2/20 0.47
HIF1A Q16665 14/20 0.45
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
EGLN2 Q96KS0 1/20 0.43
EGLN3 Q9H6Z9 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12254374 1.00 L3MBTL1 (0.52) L3MBTL1EGLN1HIF1AKDM4ESMN1; SMN2
SCHEMBL2384068 1.00 L3MBTL1 (0.52) L3MBTL1EGLN1HIF1AKDM4ESMN1; SMN2
SCHEMBL12254565 0.92 L3MBTL1 (0.48) L3MBTL1EGLN1HIF1AKDM4EEGLN2
SCHEMBL12254430 0.92 L3MBTL1 (0.48) L3MBTL1EGLN1HIF1AKDM4EEGLN2
SCHEMBL2396907 0.90 L3MBTL1 (0.47) L3MBTL1EGLN1HIF1AKDM4EALDH1A1
SCHEMBL2396909 0.90 L3MBTL1 (0.47) L3MBTL1EGLN1HIF1AKDM4EALDH1A1
SCHEMBL2383429 0.86 L3MBTL1 (0.54) L3MBTL1EGLN1HIF1AMEN1KMT2A
SCHEMBL2383427 0.86 L3MBTL1 (0.54) L3MBTL1EGLN1HIF1AMEN1KMT2A
SCHEMBL2382749 0.85 L3MBTL1 (0.55) L3MBTL1EGLN1HIF1AKDM4ESMN1; SMN2
SCHEMBL2382746 0.85 L3MBTL1 (0.55) L3MBTL1EGLN1HIF1AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960363-B1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF AMGEN INC (US) 2014-01-22 EP claimed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 L3MBTL1 4035/4885EGLN1 6/4885HIF1A 4/4885
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 L3MBTL1 4024/4885EGLN1 6/4885HIF1A 4/4885
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof EGLN3, HIF1AN, EGLN2 L3MBTL1 4024/4885EGLN1 6/4885HIF1A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.